News
AMLX
5.34
-0.28%
-0.02
AMYLYX PHARMACEUTICALS SHARES UP 1.7% ON LATE-STAGE TRIAL UPDATE FOR LOW-BLOOD SUGAR DRUG
Reuters · 5h ago
Amylyx announces design of LUCIDITY clinical trial
TipRanks · 8h ago
AMYLYX PHARMACEUTICALS INC - EXPECTS FIRST STUDY PARTICIPANT DOSED IN LUCIDITY IN Q1 2025 AND TOPLINE RESULTS IN 2026
Reuters · 8h ago
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
Barchart · 14h ago
Weekly Report: what happened at AMLX last week (1125-1129)?
Weekly Report · 2d ago
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
Barchart · 11/27 08:00
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along
Seeking Alpha · 11/25 19:40
Weekly Report: what happened at AMLX last week (1118-1122)?
Weekly Report · 11/25 09:22
Notable analyst calls this week: Roku, Nvidia and Biogen among top picks
Seeking Alpha · 11/23 14:37
Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November
Benzinga · 11/18 17:20
Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise
Seeking Alpha · 11/18 15:00
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
Benzinga · 11/18 14:59
This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Benzinga · 11/18 13:07
Amylyx Pharmaceuticals Raised to Outperform From Neutral by Baird
Dow Jones · 11/18 12:36
Amylyx Pharmaceuticals Price Target Raised to $11.00/Share From $3.00 by Baird
Dow Jones · 11/18 12:36
Baird Upgrades Amylyx Pharma to Outperform, Raises Price Target to $11
Benzinga · 11/18 12:26
Amylyx upgraded to Outperform from Neutral at Baird
TipRanks · 11/18 10:10
Strong Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising Avexitide Prospects and Stable Financial Standing
TipRanks · 11/18 10:05
Weekly Report: what happened at AMLX last week (1111-1115)?
Weekly Report · 11/18 09:21
Weekly Report: what happened at AMLX last week (1104-1108)?
Weekly Report · 11/11 09:23
More
Webull provides a variety of real-time AMLX stock news. You can receive the latest news about Amylyx Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About AMLX
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.